Exelixis, Inc. (NASDAQ:EXEL) Holdings Lowered by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. cut its stake in Exelixis, Inc. (NASDAQ:EXEL) by 11.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,031 shares of the biotechnology company’s stock after selling 1,413 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Exelixis were worth $265,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. American Century Companies Inc. lifted its holdings in Exelixis by 31.5% in the 3rd quarter. American Century Companies Inc. now owns 1,410,113 shares of the biotechnology company’s stock valued at $30,811,000 after acquiring an additional 338,021 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Exelixis by 244.5% during the fourth quarter. Exchange Traded Concepts LLC now owns 118,359 shares of the biotechnology company’s stock valued at $2,839,000 after purchasing an additional 83,999 shares during the last quarter. Seven Eight Capital LP boosted its holdings in Exelixis by 61.7% during the third quarter. Seven Eight Capital LP now owns 21,765 shares of the biotechnology company’s stock worth $476,000 after buying an additional 8,305 shares in the last quarter. NewEdge Wealth LLC acquired a new position in Exelixis in the third quarter worth approximately $10,238,000. Finally, FMR LLC increased its holdings in shares of Exelixis by 9.3% in the third quarter. FMR LLC now owns 2,884,424 shares of the biotechnology company’s stock valued at $63,025,000 after buying an additional 246,605 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Up 1.8 %

EXEL stock opened at $23.29 on Wednesday. The company has a 50 day moving average of $22.61 and a two-hundred day moving average of $22.15. The company has a market cap of $6.87 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 0.60 and a beta of 0.54. Exelixis, Inc. has a 12-month low of $18.08 and a 12-month high of $24.34.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. The business had revenue of $479.65 million for the quarter, compared to the consensus estimate of $481.23 million. On average, research analysts anticipate that Exelixis, Inc. will post 1.21 EPS for the current year.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several research reports. Barclays lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price objective for the company. in a research note on Thursday, April 11th. Royal Bank of Canada lifted their price target on Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Stifel Nicolaus upped their price objective on shares of Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. JMP Securities reissued a “market outperform” rating and issued a $27.00 target price on shares of Exelixis in a research report on Wednesday, April 10th. Finally, TheStreet upgraded shares of Exelixis from a “c+” rating to a “b-” rating in a report on Monday, March 18th. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $26.29.

Insider Buying and Selling at Exelixis

In other news, Director David Edward Johnson purchased 190,000 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was bought at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the purchase, the director now directly owns 1,100,730 shares of the company’s stock, valued at $22,785,111. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Exelixis news, Director David Edward Johnson purchased 190,000 shares of the company’s stock in a transaction dated Wednesday, February 21st. The shares were bought at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the purchase, the director now directly owns 1,100,730 shares in the company, valued at approximately $22,785,111. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan M. Garber sold 19,205 shares of Exelixis stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the sale, the director now directly owns 35,703 shares of the company’s stock, valued at approximately $857,229.03. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.